Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic Leukemia

Haematologica

Volumn 100, Issue 5, 2015, Pages 653-661

  Daver, Naval ^a   Thomas, Deborah ^a   Ravandi, Farhad ^a   Cortes, Jorge ^a   Garris, Rebecca ^a   Jabbour, Elias ^a   Garcia Manero, Guillermo ^a   Borthakur, Gautam ^a   Kadia, Tapan ^a   Rytting, Michael ^a   Konopleva, Marina ^a   Kantarjian, Hagop ^a   O’Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; PROTEIN P190; VINCRISTINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY; CLINICAL TRIAL; FOLLOW UP; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETREATMENT; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FOLLOW-UP STUDIES; HUMANS; IMATINIB MESYLATE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RETREATMENT; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84929148590     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118588     Document Type: Article

References (50)

1. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98(7):1337-1354.
2. Bloomfield CD, Goldman AI, Alimena G, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood. 1986; 67(2):415-420.
3. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A populationbased cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010; 115(2):206-214.
4. Burmeister T, Schwartz S, Bartram CR, et al. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112(3):918-919.
5. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosomepositive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000;36(3-4):263-273.
6. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-2366.
7. Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992;64(2):97-100.
8. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995; 85(8):2025-2037.
9. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80(9):1717-1726.
10. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome- positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG 2993. Blood. 2009; 113(19):4489-4496.
11. Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of Philadelphia chromosome- positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: A 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112(3):903-909.
12. Burke MJ, Trotz B, Luo X, et al. Allohematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone marrow transplantation. 2009;43(2):107-113.
13. Fielding AK. How I treat Philadelphia chromosome- positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409-3417.
14. Goldstone AH, Richards SM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111(4):1827-1833.
15. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843-850.
16. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosomepositive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408-1413.
17. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosomepositive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396-4407.
18. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomepositive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070-2077.
19. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCRABL- positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460-466.
20. Rousselot P, Cayuela JM, Hayette S, et al. Dasatinib (Sprycel?) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive All (Ewall-Ph-01): Analysis of Response and Resistance. Haematol-Hematol J. 2009; 94:195-196.
21. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL 0031. Leukemia. 2014;28(7):1467-1471.
22. Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia. 2009;23(1):190-194.
23. Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia. 2005;19(4):628-635.
24. Mizuta S, Matsuo K, Nishiwaki S, et al. Pretransplant administration of imatinib for allogeneic hematopoietic stem cell transplantation in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood. Blood. 2014;123(15):2325-32.
25. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2005; 105(9):3449-3457.
26. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000; 18(3):547-561.
27. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86(6):2091-2097.
28. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-1037.
29. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronicphase chronic myelogenous leukemia. Clin Cancer Res. 2003;9(1):160-166.
30. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122(4):254-261.
31. Luthra R, Sanchez-Vega B, Medeiros LJ. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol. 2004;17(1):96-103.
32. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome- positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122(7):1214-21.
33. Kaplan EL, Meier P. Nonparametric- Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457-481.
34. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
35. Hoelzer D, Gokbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol. 2002;39(4 Suppl 3):32-37.
36. Wassmann B, Pfeifer H, Scheuring U, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 2002; 16(12):2358-2365.
37. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100(6):1965-1971.
38. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-ablpositive cells. Blood. 2000;96(9):3195-3199.
39. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97(7):1999-2007.
40. Delannoy A, Delabesse E, Lheritier V, et al. The Long-Term Outcome of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph Plus All) in the Imatinib Era. Haematol-Hematol J. 2009;94:30-31.
41. Pfeifer H, Wassmann B, Bethge WA, et al. Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL). Blood. 2011;118(21):112-113.
42. Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95(1):87-95.
43. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644-3652.
44. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphiachromosome- positive acute lymphoblastic leukaemia (EsPhALL): a randomised, openlabel, intergroup study. Lancet Oncol. 2012; 13(9):936-945.
45. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531): 876-880.
46. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110(2):727-734.
47. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci Usa. 2006;103(45):16870-16875.
48. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT- 1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108(2):697-704.
49. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
50. Kim DY, Joo YD, Lee JH, et al. Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. Blood. 2011;118(21):658-659.